{"abstract":"The National Cancer Institute (NCI), National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive, sublicensable patent license to Stanford University, (\"Stanford\"), a non-profit university located in California, in its rights to the inventions and patents listed in the SUPPLEMENTARY INFORMATION section of this notice.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2020/01/24/2020-01154.html","cfr_references":[],"citation":"85 FR 4332","comment_url":null,"comments_close_on":"2020-02-10","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the NCI Technology Transfer Center February 10, 2020 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2020-01154","effective_on":null,"end_page":4332,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2020/01/24/2020-01154.xml","html_url":"https://www.federalregister.gov/documents/2020/01/24/2020-01154/prospective-grant-of-exclusive-patent-license-antibody-based-therapeutics-and-chimeric-antigen","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2020-01154?publication_date=2020-01-24","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2020-01-24/2020-01154/mods.xml","not_received_for_publication":null,"page_length":1,"page_views":{"count":180,"last_updated":"2026-07-27 00:15:04 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2020-01-24/pdf/2020-01154.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2020-01154.pdf?1579787122","publication_date":"2020-01-24","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2020/01/24/2020-01154.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-02-28T18:49:22Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":4332,"subtype":null,"title":"Prospective Grant of Exclusive Patent License: Antibody-Based Therapeutics and Chimeric Antigen Receptors Targeting Glypican-2","toc_doc":"Antibody-Based Therapeutics and Chimeric Antigen Receptors Targeting Glypican2","toc_subject":"Prospective Grant of Exclusive Patent License:\n","topics":[],"type":"Notice","volume":85}